drugset
drugset / Trial / NCT04430036

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

NCT04430036 ↗

Phase 2 Terminated 4 enrolled The University of Texas Health Science Center at San Antonio
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder cancer prior to radical cystectomy.

Timeline

Start
2020-10-14
Primary completion
2021-10-18
Completion
2022-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Balstilimab Monoclonal antibody — —
Subject Cisplatin Other / unclassified — —
Subject Gemcitabine Small molecule — —
Subject Zalifrelimab Monoclonal antibody — —

Indications

urinary bladder cancer